ArticleBritish journal of pharmacology1994
Classical and atypical binding sites for beta-adrenoceptor ligands and activation of adenylyl cyclase in bovine skeletal muscle and adipose tissue membranes.
Article in British journal of pharmacology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 49 citations in OpenAlex.
- Beta-Adrenergic Agonists, Dietary Protein, and Rumen Bacterial Community Interactions in Beef Cattle: A Review.Veterinary sciences · 2023Review
- Short Communication: Beta-adrenergic agonists alter oxidative phosphorylation in primary myoblasts.Journal of animal science · 2022Article
- Lubabegron fumarate acts as a β-adrenergic receptor antagonist in cultured bovine intramuscular and subcutaneous adipocytes.Journal of animal science · 2022Article
- Characterization of β-adrenergic receptors in bovine intramuscular and subcutaneous adipose tissue: comparison of lubabegron fumarate with β-adrenergic receptor agonists and antagonists.Journal of animal science · 2021Article
- Comparison of beta-ligands used in cattle production: structures, safety, and biological effects.Journal of animal science · 2021Article
- Historical Overview of the Effect of β-Adrenergic Agonists on Beef Cattle Production.Asian-Australasian journal of animal sciences · 2014Article
- Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats.The Journal of physiology · 2004Article
- Biphasic effects of the beta-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle.British journal of pharmacology · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. The radioligand [125I]-iodocyanopindolol ([125I]-ICYP) was used under standard ligand binding conditions, to detect beta 1- and beta 2-adrenoceptors in membrane preparations from bovine skeletal muscle and adipose tissue. High concentrations of [125I]-ICYP were also used, to identify an 'atypical' binding site in skeletal muscle. Finally, adenosine 3':5'-cyclic monophosphate (cyclic AMP) production was measured in the same membrane preparations, to determine the relationship between the beta-adrenoceptor sub-types present and the production of this second-messenger. 2. According to the results of radioligand binding studies, both skeletal muscle and adipose tissue membranes have beta 2-adrenoceptors, characterized by a high affinity for the beta 2-selective antagonist, ICI 118551 (pK 8.3 and 8.6 respectively); and a low affinity for the beta 1-selective antagonist CGP 20712A (pK 5.2 in both tissues). Antagonism of (-)-isoprenaline-stimulated cyclic AMP production by low concentrations of ICI 118551, yielded pseudo pA2 values in muscle and adipose tissue of 7.6 and 8.7 respectively, confirming that beta 2-adrenoceptors in these tissues are linked to the production of the second-messenger. 3. Although beta 1-adrenoceptors could not be detected in either skeletal muscle or adipose tissue membranes by use of ligand binding techniques, high pseudo pA2 values were obtained (8.0 and 8.2 respectively), when CGP 20712A was used to block the stimulation of cyclic AMP production by (-)-isoprenaline. This finding is consistent with the presence in both tissues of a population of beta 1-adrenoceptors which is small, but efficiently coupled to the second-messenger. 4.In addition to identifying standard beta 1- and beta 2-adrenoceptors, it was also established that skeletal muscle membranes have an 'atypical' binding site which has a relatively low affinity for [125]-ICYP(pK8.84), but which exists in abundance. At high concentrations of radioligand, the 'atypical' site accounted for 89% of the total [125I]-ICYP binding sites present.5. The results of second-messenger studies do not support the hypothesis that skeletal muscle or adipose tissue membranes contain functional beta 3-adrenoceptors: based on the failure of a beta 3-adrenoceptor-selective agonist (BRL 37344) to stimulate cyclic AMP production, the absence of a biphasic response to (-)-isoprenaline, and the observation that cyclic AMP production was not resistant to blockade by either ICI 118551 or CGP20712A.6. It is concluded that data from radioligand binding studies do not accurately reflect the contribution made by beta 1- and beta 2-adrenoceptors to cyclic AMP production in bovine skeletal muscle and adipose tissue membranes. Furthermore, the 'atypical' [125I]-ICYP binding site identified in bovine skeletal muscle does not represent a functional bovine beta 3-adrenoceptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.